Kyverna Therapeutics (KYTX) Chief Commercial Officer listed on Form 3

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. filed a Form 3 identifying Nadia Dac as a reporting person in her role as Chief Commercial Officer. This Form 3 serves as an initial statement of insider status for SEC reporting. The provided data show no reported share purchases, sales, or other transactions in this filing.

Key Terms

Form 3, Chief Commercial Officer, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Commercial Officer financial

""officer_title": "Chief Commercial Officer""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

reporting person regulatory

""reportingPersons": [{"name": "Dac Nadia""

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dac Nadia

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON STREET, SUITE 550

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/04/2026

3. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Marc Grasso, as Attorney-in-Fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Kyverna Therapeutics (KYTX) Form 3 filing show?

The Form 3 shows that Nadia Dac, Chief Commercial Officer of Kyverna Therapeutics, is now a reporting insider. It establishes her status for future SEC disclosures but lists no share purchases, sales, or derivative exercises in this filing.

Who is the reporting person in Kyverna Therapeutics (KYTX) Form 3?

The reporting person is Nadia Dac, who serves as Chief Commercial Officer of Kyverna Therapeutics. As an executive officer, she must report certain holdings and future transactions in company securities under SEC insider reporting rules.

Does the Kyverna Therapeutics (KYTX) Form 3 include any stock transactions?

No. The summarized data for this Form 3 show zero buys, zero sells, and no derivative exercises. It functions purely as an initial insider status filing for Chief Commercial Officer Nadia Dac, without recording any specific security trades.

Why is a Form 3 important for Kyverna Therapeutics (KYTX) insiders?

Form 3 is the initial insider ownership statement required when someone becomes an officer, director, or large shareholder. It creates a baseline for future Forms 4 and 5, which will detail any subsequent trades or equity-related transactions.

What future filings may follow this Kyverna Therapeutics (KYTX) Form 3?

After a Form 3, insiders like Chief Commercial Officer Nadia Dac typically file Form 4 for most transactions and Form 5 annually if needed. Those later filings would disclose any actual purchases, sales, grants, or derivative exercises.